Shield Therapeutics PLC Results of 2021 Annual General Meeting (2902C)

TIDMSTX

RNS Number : 2902C

Shield Therapeutics PLC

17 June 2021

Shield Therapeutics plc

("Shield" or the "Group" or the "Company")

Results of 2021 Annual General Meeting

London, UK, 17 June 2021: Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru (R) /Accrufer(R) (ferric maltol), announces the results of the voting for each of the resolutions as set out in the Notice of Annual General Meeting 2021. The Board reports that resolutions 1 to 10 passed as ordinary resolutions and resolutions 11 and 12 were passed as special resolutions, full details are shown below.

The following table shows the votes cast on each resolution:

 
                   VOTES FOR      %     VOTES AGAINST    %     VOTES WITHELD 
 Resolution 1     115,096,905   99.94           6,544   0.01         883,488 
                 ------------  ------  --------------  -----  -------------- 
 Resolution 2     115,083,904    99.2         866,271   0.75          36,762 
                 ------------  ------  --------------  -----  -------------- 
 Resolution 3     115,083,904    99.2         866,271   0.75          36,762 
                 ------------  ------  --------------  -----  -------------- 
 Resolution 4     115,927,366   99.93          25,810   0.02          36,761 
                 ------------  ------  --------------  -----  -------------- 
 Resolution 5     115,086,905    99.2         866,271   0.75          36,761 
                 ------------  ------  --------------  -----  -------------- 
 Resolution 6     115,082,443    99.2         867,732   0.75          36,762 
                 ------------  ------  --------------  -----  -------------- 
 Resolution 7     115,083,904    99.2         866,271   0.75          36,762 
                 ------------  ------  --------------  -----  -------------- 
 Resolution 8     115,114,781    99.2         866,695   0.75           5,461 
                 ------------  ------  --------------  -----  -------------- 
 Resolution 9     115,956,508   99.93          27,207   0.02           3,222 
                 ------------  ------  --------------  -----  -------------- 
 Resolution 10    115,905,527   99.91          47,834   0.04          33,576 
                 ------------  ------  --------------  -----  -------------- 
 Resolution 11    115,719,269   99.75         228,432    0.2          39,236 
                 ------------  ------  --------------  -----  -------------- 
 Resolution 12    114,882,135   99.03       1,065,566   0.92          39,236 
                 ------------  ------  --------------  -----  -------------- 
 

Notes:

   1.    Number of shares in issue 215,837,965. 
   2.    Details of the votes received on the resolutions are available on the Company's website: https://www.shieldtherapeutics.com/corporate-documents/ . 
   3.    Shield Therapeutics plc LEI: 213800G74QWY15FC3W71. 

For further information please contact:

 
 Shield Therapeutics plc                              www.shieldtherapeutics.com 
 Greg Madison, CEO                                           [phone] 
 Lucy Huntington-Bailey (General 
  Counsel and Company Secretary) 
 
   Nominated Adviser and Joint 
   Broker 
 Peel Hunt LLP 
 James Steel/Dr Christopher 
  Golden                                                     [phone] 
 
 
   Joint Broker 
   finnCap Ltd 
   Geoff Nash/Matt Radley/Alice 
   Lane                                                      [phone] 
 
 
   Financial PR & IR Advisor 
 Walbrook PR                        [phone] or [e-mail] 
                                           [phone] / [phone] 
 Paul McManus/Lianne Cawthorne                                               303 
 

About Shield

Shield is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru(R) /Accrufer(R) (ferric maltol), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia.

Shield's lead product, Feraccru(R)/Accrufer(R), has been approved for use in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid-2030s. The Group plans to launch Accrufer(R) in the US during 2021 through a highly experienced sales and marketing team. Feraccru(R) is already being commercialised in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru(R)/Accrufer(R) in China, Hong Kong, Macau and Taiwan.

For more information, please visit www.shieldtherapeutics.com . Follow Shield on Twitter @ShieldTx

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGMZGMVFNLGMZM

(END) Dow Jones Newswires

June 17, 2021 09:30 ET (13:30 GMT)